Reports
Reports
Sale
The global knee cartilage repair market size attained a value of about USD 2.81 billion in 2022, driven by the rising demand of minimally invasive knee surgeries across the globe. The market value is anticipated to grow at a CAGR of 6.24% during the forecast period of 2023-2031 to attain a market value of USD 4.84 billion by 2031.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
In orthopaedics, articular cartilage injuries are a serious clinical concern. With high incidence of injury and limited intrinsic tissue repair potential, a large population of youthful and healthy individuals are left in danger of developing degenerative osteoarthritis (OA). It is estimated that over 30% of Americans above 45 years of age experience some type of knee pain.
Cartilage is a type of connective tissue found in several parts of the body. It is relatively easy to damage, despite being a robust and flexible material.
Chondral lesions are a common occurrence in a significant majority of the population. Chondroplasty is a common procedure performed to treat chondral injuries. It involves the removal of damaged tissue. While this approach offers symptomatic relief in the short-run, the remaining tissue becomes more prone to deterioration and faster degeneration.
Microfracture, which entails piercing the subchondral bone to enable the bone marrow to plug the defect, is another prevalent procedure. However, it leads to the creation of mechanically inferior fibrocartilage tissue.
Mosaicplasty, also known as osteochondral autologous transplantation (OATs), is an open treatment that involves harvesting osteochondral plugs from non-weight-bearing areas and transplanting them into the deficiency. However, transplanted cartilage has been shown to produce donor site morbidity; it does not combine well with existing cartilage, and degenerates with time.
Modern cartilage regeneration techniques include autologous chondrocyte implantation (ACI), matrix-associated autologous chondrocyte implantation (MACI), and autologous matrix-induced chondrogenesis (AMIC).
In the MACI technique, a two-stage procedure is followed. It is an advancement of the ACI approach. Healthy cartilage cells are extracted from the patient, then expanded and seeded in a collagen matrix; these are then re-implanted into the cartilage defect.
AMIC is a single-stage treatment that involves implanting a cell-free collagen matrix into a cartilage defect and then microfracturing it.
While these treatment options have provided better outcomes than conventional techniques such as chondroplasty and microfracture, they largely remain limited to a minority of the patient population with close to ideal surgical conditions. Such patients are most likely to benefit significantly after an intervention. The larger population with more severe symptoms, or those who suffer from co-morbidities precluding them from these cartilage repair interventions are limited to short-term palliative treatment alternatives, such as oral non-steroidal anti-inflammatory drugs (NSAIDs) or intra-articular injections of corticosteroids or hyaluronic acid. Although these treatments offer short-term relief from pain and inflammation, the long-term solution for such patients seems to be total joint replacement.
Several leading companies such as Stryker Corporation, Smith and Nephew, Vericel Corporation are engaged in providing treatment solutions for joint problems. In 2017, Vericel Corporation announced the first MACI implant in USA to repair symptomatic single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Smith and Nehphew offer CARGEL Bioscaffold - an easy, ready-to-use product employed in a single-step bone marrow stimulation procedure to provide superior cartilage repair. Stryker Corporation introduced a cementless total knee system - cementless total knee arthroplasty (TKA) with Triathlon Tritanium – that is becoming quite popular. The system has been reported to deliver good clinical outcomes and significant pain reduction. Such advancements in treatment systems are expected to boost the market. North America, Europe and Asia Pacific are expected to be key markets.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
By modality, the market is segmented into:
By treatment type, the market is classified into:
By end-user, the market is divided into:
By region, the market is segmented into:
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The report presents a detailed analysis of the following key players in the market, looking into their capacity, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.
REPORT FEATURES | DETAILS |
---|---|
Base Year | 2022 |
Historical Period | 2016-2022 |
Forecast Period | 2023-2031 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Treatment Modality |
|
Breakup by Surgery |
|
Breakup by Devices |
|
Breakup by Application |
|
Breakup by End User |
|
Breakup by Region |
|
Market Dynamics |
|
Competitive Landscape |
|
Companies Covered |
|
Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Knee Cartilage Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Knee Osteoarthritis Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Knee Osteoarthritis Epidemiology (2016-2031)
5.3 Europe Knee Osteoarthritis Epidemiology (2016-2031)
5.4 Asia-Pacific Knee Osteoarthritis Epidemiology (2016-2031)
5.5 Latin America Knee Osteoarthritis Epidemiology (2016-2031)
5.6 Middle East & Africa Knee Osteoarthritis Epidemiology (2016-2031)
6 Global Knee Cartilage Repair Market Overview
6.1 Global Knee Cartilage Repair Market Historical Value (2016-2022)
6.2 Global Knee Cartilage Repair Market Forecast Value (2023-2031)
7 Global Knee Cartilage Repair Market Landscape
7.1 Knee Cartilage Repair: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Knee Cartilage Repair: Product Landscape
7.2.1 Analysis by Treatment Modality
7.2.2 Analysis by Surgery
7.2.3 Analysis by Devices
7.2.4 Analysis by Application
7.2.5 Analysis by End User
8 Knee Cartilage Repair Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Knee Cartilage Repair Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Knee Cartilage Repair Market Segmentation
11.1 Global Knee Cartilage Repair Market by Treatment Modality
11.1.1 Market Overview
11.1.2 Cell-based
11.1.2.1 Chondrocyte Transplantation
11.1.2.2 Growth Factor Technology
11.1.3 Noncell- Based
11.1.3.1 Tissue Scaffolds
11.1.3.2 Cell-Free Composites
11.2 Global Knee Cartilage Repair Market by Surgery
11.2.1 Market Overview
11.2.1.1 Osteochondral Autograft Transplantation
11.2.1.2 Osteochondral Allograft Transplantation
11.2.1.3 Microfracture
11.2.1.4 Drilling
11.2.1.5 Abrasion Arthroplasty
11.2.1.6 Autologous Chondrocyte Implantation
11.2.1.7 Others
11.3 Global Knee Cartilage Repair Market by Devices
11.3.1 Market Overview
11.3.2 Implants
11.3.3 Osteotomy
11.3.4 Bone Grafts
11.3.5 Arthroscopy
11.3.6 Resurfacing
11.3.7 Arthrodesis
11.3.8 Others
11.4 Global Knee Cartilage Repair Market by Application
11.4.1 Market Overview
11.4.2 Osteoarthritis
11.4.3 Rheumatoid Arthritis
11.4.4 Osteonecrosis
11.4.5 Fractures
11.4.6 Bone Tumors
11.4.7 Others
11.5 Global Knee Cartilage Repair Market by End User
11.5.1 Market Overview
11.5.2 Hospitals
11.5.3 Orthopedic Centres
11.5.4 Ambulatory Surgical Centres
11.5.5 Others
11.6 Global Knee Cartilage Repair Market by Region
11.6.1 Market Overview
11.6.2 North America
11.6.3 Europe
11.6.4 Asia Pacific
11.6.5 Latin America
11.6.6 Middle East and Africa
12 North America Knee Cartilage Repair Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Knee Cartilage Repair Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Knee Cartilage Repair Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Knee Cartilage Repair Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Knee Cartilage Repair Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Stryker
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 Zimmer Biomet
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 B. Braun Melsungen AG
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 The Future of Biotechnology
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 MEDIPOST
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 Vericel Corporation
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 CONMED Corporation
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Meril Life Sciences Pvt. Ltd.
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Medacta International
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 Teijin Nakashima Medical Co., Ltd.
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
23.11 EVOLUTIS INDIA PVT. LTD.
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
23.11.5 Certifications
23.12 Regentis Biomaterials Ltd.
23.12.1 Financial Analysis
23.12.2 Product Portfolio
23.12.3 Demographic Reach and Achievements
23.12.4 Mergers and Acquisitions
23.12.5 Certifications
23.13 Auxein Medical.
23.13.1 Financial Analysis
23.13.2 Product Portfolio
23.13.3 Demographic Reach and Achievements
23.13.4 Mergers and Acquisitions
23.13.5 Certifications
24 Knee Cartilage Repair - Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
The market is estimated to grow at a CAGR of 4.8% between 2023 and 2031.
The major drivers of the market include the rising cases of injuries and accidents, rising healthcare expenditure, growing health awareness, susceptibility of knee damage among the geriatrics, and rapid development of hospitals, nursing homes, and clinics.
The technological advancements in the healthcare sector are expected to be a key trend guiding the growth of the industry.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
Cell-based and non-cell based are the different treatment modalities considered in the market report.
Palliative and intrinsic repair stimulus are the significant treatment types included in the market report.
Hospitals, ambulatory surgical centers, and orthopaedic clinics, among others are the major end users of the product.
The major players in the industry are Stryker Corporation, Smith & Nephew plc, Vericel Corporation, B. Braun Melsungen AG, and Arthrex, Inc, among others.
Mini Report
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.